Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, and Relative Bioavailability of a Single Dose of Spesolimab Via Two Subcutaneous Modes of Delivery in Healthy Subjects (Mono-centric, Randomised, Parallel Group Design)

Next Previous
Trial Profile

Safety, Tolerability, and Relative Bioavailability of a Single Dose of Spesolimab Via Two Subcutaneous Modes of Delivery in Healthy Subjects (Mono-centric, Randomised, Parallel Group Design)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spesolimab (Primary)
  • Indications Crohn's disease; Generalised pustular psoriasis; Hidradenitis suppurativa; Netherton Syndrome; Palmoplantar pustulosis; Pyoderma gangrenosum; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 22 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 21 Nov 2024 Planned End Date changed from 17 Jan 2025 to 24 Jan 2025.
  • 21 Nov 2024 Planned primary completion date changed from 17 Jan 2025 to 24 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top